Inhibikase Therapeutics Inc. (IKT), a clinical-stage pharmaceutical company, has a clinical trial catalyst to watch in the coming weeks related to its 201 Trial.
The 201 Trial is a phase II study evaluating the company's drug candidate Risvodetinib (also known as IkT-148009) in untreated Parkinson's disease. A total of 126 patients have been randomized in the trial, 120 of which have completed the 12-week double-blind dosing period. Topline data from this study is due this quarter.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.